Method for experimental prevention of age-related changes in hepatic tissue. RU patent 2482873.
 Silibilin component for treating hepatitis / 2482844Claimed are: application of silibinin component of general formula (I) for obtaining medication for parenteral introduction for trweatment of viral hepatitis, with medication optionally containing cyclodextrin and/or phospholipid, and set of similar purpose, which includes said silibinin component and other medication, representing one or several pharmaceutical agents from: arginine, glutamate, silymarin, citiolone, epodemiol, ornithine oxoglurate, tidiacic arginine, myoinosite, methionine and N-acetyl methionine, choline, ornithine aspartate, cyanidanol, thiopronin, betaine, cyanocobalamin, leucine, levolose, acyclovir, idoxuridine, vidarabine, ribavirin, ganciclovir, famciclovir, valaciclovir, cidofovir, penciclovir, valganciclovir, brivudin, interferon. Medication preferably does not contain silidianin, and/or silicristin, and/or isosilibinin. |
 Conjugated lipid derivatives / 2480447Invention refers to a new lipid compound of general formula , wherein n=0; R1 and R2 are identical or different, and may be specified in a group of substitutes consisting of a hydrogen atom, a C1-C7alkyl group, a halogen atom and a C1-C7alkoxy group; X represents COR3 or CH2OR4, wherein R3 is specified in a group consisting of hydrogen, hydroxy, C1-C7alkoxy and amino; and R4 is specified in a group consisting of hydrogen, C1-C7alkyl or C1-C7acyl, Y represents C9-C21 alkene with one or more double bonds in E- or Z-configurations with the chain Y being unsubstituted and containing a double bond in the ω-3 position; provided R1 and R2 cannot simultaneously represent a hydrogen atom. |
|
Method for correction of ischemic disorders caused by reperfusion liver injury / 2479872 Correction of ischemic disorders caused by reperfusion liver injury in experiment in white Wistar male rats involves modelling an ischemic and reperfusion liver injury. 30 Minutes before, L-norvalin arginase blocker 10 mg/kg is introduced intraperitoneally, and distant ischemic pre-conditioning is conducted. Then, another dose of L-norvalin arginase blocker is introduced immediately after liver ischemia. |
 Method of secondary prevention of hepatobiliary dysfunctions in children in conditions of increased contamination of biomedia with phenol, formaldehyde, methanol / 2478395Invention relates to medicine and is intended for prevention of hepatobiliary dysfunctions in children, living in conditions of contamination of atmospheric air with phenol, formaldehyde, methanol. Complex of medications ia applied. Eslidin in introduced perorally in 14-day course in age dosage from 3 to 7 years - 1 capsule 2 times per day, over 7 years - 1 capsule 3 times per day. Canephron N is introduced perorally, diluted in small amount of water, 2 times per day, to children of pre-school age in dose 10 drops, of school age - 20 drops per day with 10 day course; Flamin is introduced perorally 30 minutes before meal in dose 1-2 tablets per day with 10 day course; Jungle is introduced perorally during or after meal in dose 1 tablet 1 time per day with 21 day course; Immunal is introduced perorallyt 1 time per day with 10 day course in age dosage from 1 year to 6 years - 5-10 drops, from 6 to 12 years - 10-15 drops, over 12 years - in dose 20 drops. Course is repeated 1 time per year in children with light degree of disease course and 2 times per year in case of middle-severe disorders. |
 Indole compounds as cell necrosis inhibitors / 2477282Invention refers to new indole compounds of formula: |
 Use of quartenary pyridinium compounds for vasoprotection and/or hepatoprotection / 2477132Invention refers to using a compound of formula (I): |
|
Treatment product for pharmacorrection of animal hepatopathy / 2476233 Invention refers to veterinary science and may be used for prevention and pharmacorrection of animal hepatopathy, as well as for improving body productivity and resistance. The treatment product for pharmacorrection of hepatopathy contains holy thistle cakes, germinated oats and ribotan in the following proportions, wt %: germinated oats - 20.0, ribotan - 35.0, thistle cakes - 45.0. |
 Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme / 2474576Invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, where Q is phenyl or pyridinyl; A is pyrazolyl or triazolyl, where each A is independently additionally unsubstituted or substituted with 1 or 2 substitutes represented by Ra, or A is formula (a); Va is C(R4), Vb is N or C(R5) and Vc is N; or Va is N, Vb is C(R5) and Vc is N or C(R6); R4 is hydrogen, R5 is hydrogen, C1-6alkyl, -ORb, -SRb, aryl, selected from phenyl, heteroaryl, selected from thienyl, or cycloalkyl, selected from cyclopropyl; R6 is hydrogen or aryl, selected from phenyl; R7 is hydrogen or C1-6alkyl; R3 is hydrogen, C1-3alkyl, -OH, -S(O)2R1, or heteroaryl, selected from tetrazolyl, where the heteroaryl is bonded to a nitrogen atom through a ring carbon atom; Rb, Rx, Ry, Rza, Rzb, Rw, Re, Rk, Rm, Rn, Rq and R1, in each case, are independently hydrogen, C1-3alkyl or C1-3haloalkyl; and Rf, in each case, is independently hydrogen, C1-3alkyl or -OH (the rest of the substitutes assume values given in the claim). The invention also relates to a pharmaceutical composition, having inhibiting action on DGAT-1, which contains a compound of formula (I), and a treatment method. |
 Novel tetrahydroisoquinoline derivative, pharmaceutical composition based thereon, use thereof and method of treating and/or preventing disease / 2474575Invention relates to novel tetrahydroisoquinoline derivatives of general formula (I) or pharmacologically acceptable salts thereof, where R1 is a phenyl aminocarbonyl group which can be substituted with 1-3 groups independently selected from a substituting group A, a heteroaryl aminocarbonyl group, where the heteroaryl is pyridine, pyrazine, thiazole, pyrazole or isoxazole, which can be substituted with 1 group selected from a substituting group A, benzoxazol-2-yl group, which can be substituted with 1 group selected from a substituting group A, benzothiazol-2-yl group, (C1-C6 alkyl which can be monosubstituted with a C3-C6 cycloalkyl group), aminocarbonyl group, (C3-C6 cycloalkyl)aminocarbonyl group or adamantyl aminocarbonyl group; R2 independently represents a C1-C6 alkyl group; R3 is a heterocyclic group, where the heterocycle is oxazole, oxadiazole, pyrazole, isoxazole or tetrazole, which can be substituted with 1 group selected from a substituting group A, a group of formula -C(=O)-O-R4, or a group of formula -C(=O)-N(R5)R6; R4 is a hydrogen atom, a C1-C6 alkyl group which can be substituted with 1-2 groups independently selected from a substituting group B; R5 is a hydrogen atom, a C1-C6 alkyl group which can be substituted with 1 group selected from a substituting group B, a C3-C6 cycloalkyl group which is monosubstituted with a carboxyl group, or a heterocyclic group, where the heterocycle is tetrazole, which can be substituted with 1 group selected from a substituting group A; R6 is a hydrogen atom or a C1-C6 alkyl group; in those cases when both R5 and R6 represent a C1-C6 alkyl group, which can be substituted with 1 group selected from a substituting group B, their carbon atoms can be bonded to each other to form a 5-member saturated ring; X is an oxygen atom, a methylene group, a group of formula -NH-, a methylene group which is monosubstituted with a C1-C6 alkyl group, or a group of formula -N(R7)-; R7 is a C1-C6 alkyl group; L is a single bond, a methylene group, a 1,1-dimethylmethylene group, an ethylene group, a group of formula - CH=, or a methylene group which is monosubstituted with a C1-C6 alkyl group; … denotes a single bond or a double bond (however, … denotes a single bond when L is a group of formula -CH=); m equals 1 or 2; n equals 0 or 1; substituting group A is a group of substitutes selected from a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, a C1-C6 alkylthio group, a carboxyl group, a di-(C1-C6 alkyl)amino group, a cyano group, a hydroxy group, a C1-C6 alkylthionyl group and an oxo group; and substituting group B is a group of substitutes selected from a carboxyl group and a hydroxy group. The invention also relates to a pharmaceutical composition based on the compound of formula (I), use of the compound of formula (I) and a method of treating and/or preventing a disease. |
 Method of treatment of liver metastases / 2474423Invention refers to medicine, namely oncology, and may be used for treating liver metastases. That is ensured by introducing the hydrophobic suspension Teraftal® containing a radiopaque substance into a hepatic artery. The introduction is aided by X-ray. It is followed by the introduction of ascorbic acid started one day after the arterial embolisation and continued for seven days daily. A single dose of ascorbic acid makes 100 mg. |
 Enzymatic anticancer therapy / 2481855Group of inventions refers to new methods of treating and suppressing the tumour growth, specifically malignant solid tumours by administering an effective amount of adenosine aminase conjugated with a non-antigen polymer for the purpose of the tissue adenosine and deoxyadenosine level recovery. |
 Enteric-coated glucosinolates and beta-thioglucosidases / 2477126Present invention refers to a composition in the form of particles containing enteric-coated glucosinolates and beta-thioglucosidases. The present invention also represents a method for glucosinolate transformation into isothiocyanate in a small intestine providing oral introduction of an enteric-coated composition of a chemoprotector precursor containing enteric-coated glucosinolates and beta-thioglucosidases into a patient. In the other aspect, the uncoated glucosinolate and beta-tioglucosidase particles may be introduced into an enteric-coated capsule. Preferentially, glucosinolate is glucoraphanin, and beta-thioglucosodase is myrosinase. |
 Hyaluronidase and method for using it / 2471867There are presented hyaluronidase protein of molecular weight approximately 44±1 kDa containing an amino acid sequence at least by 90% identical to an amino acid sequence containing SEQ ID NO: I, SEQ ID NO: 2 and SEQ ID NO: 4 presented in the description, as well as DNA coding it. What is described is a pharmaceutical medical composition for increasing tissue penetration and decreasing connective tissue viscosity containing an effective amount of recovered said hyaluronidase and a pharmaceutically acceptable excipient, a carrier, a solvent and an additive agent. The following methods are presented: 1) prevented or minimised cicatrisation involving the local introduction of said pharmaceutical composition; 2) reduced wrinkle formation by decreasing connective tissue viscosity involving the local introduction of said pharmaceutical composition; 3) relieved discomfort and pain caused by rheumatic arthritis, systemic sclerosis, peritendinitis or tendovaginitis involving the introduction of said pharmaceutical composition into a patient; 4) improved agent penetration into tissue involving the introduction of the agent together with the pharmaceutical composition into an individual. |
 Method of treating dystrophic diseases of eye retina / 2471454Invention relates to medicine, namely to ophthalmology, and can be used for treatment of dystrophic diseases of retina. At the first stage of treatment, sanitisation of nose cavities and distant ultrasound jet-aerosol spraying of ozone/NO-containing medication on their mucosa. After that, performed is superficial contact ultrasound processing of regional lymphatic nodes of face and neck lymph region on abducting from eye lymphatic ways through intermediate padding, saturated with ozone/NO-containing medication. At the second stage solution of superoxide dismutase is introduced in parabulbar and endonasal way. After that, similar contact ultrasound processing is performed. At the third stage into nasal cavity introduced is photochrome device, irradiating in regions of visible parts of spectrum of different colours, and endonasal irradiation of retina is performed with turn of photochrome device in different planes relative to the centre of eye orbit. At the fourth stage of treatment superficial contact processing of said lymphatic zones by means of thermo- and photochromo-ultrasound applicator is performed. |
 Composition reducing immune stress (versions), method for improving growth indicators and method for reducing immune stress thereby / 2465005Group of inventions refers to veterinary science and growing and feeding animals. A composition reducing immune stress orally introduced in an animal in the form of feed contains at least one enzyme reducing immune stress which decreases a level of a positive acute phase protein in said animal, increases a level of a negative acute phase protein in said animal and/or improves growth indicators in said animals, other than phospholipase or hemicellulose such as 13-mannanase in a carrier acceptable for the oral use in the amount of min. 20 international units/kilogram of the composition; the compositions are presented in a liquid or solid form; what is also presented is a method for improving growth indicators of an animal and a method for reducing immune stress. |
 Analgesic / 2452510What is offered is using hyaluronidase immobilised by electron-beam synthesis nanotechnology as an analgesic. |
 Method for immune correction in children suffering appendicular peritonitis / 2446820Invention refers to medicine, particularly paediatric surgery. A method for immune correction in children suffering appendicular peritonitis consists in the postoperative single intramuscular introduction of Longidase 3000 IU on the 3rd, 6th, 9th, 12th and 15th days. |
|
Method of skin sarcoidosis treatment / 2442588 Invention refers to dermatology and can be used in dermatological practice to treat patients with skin sarcoidosis. For this diprospan is used intradermally in single dose of 0.14-7.0 mg/cm with interval of 19-23 days between injections. The course is 3-5 injections. At the same time intramuscularly used longidase of 1500-3000 ME. Additionally in the middle of interval between injections of diprospane one-time longidase is used in the same dosage. |
|
Method for blood purification from dna-containing immune complexes using combined sorbent / 2441674 FIELD: medicine. SUBSTANCE: invention is referred to the area of medicine, namely rheumatology, immunology and biotechnology and is related to lowering of content of DNA-containing circulating immune complexes in blood. In order to do that the blood is filtered through the original combined sorbent which is a composition consisting of granulated drug with immobilized DNAse I and granulated drug with immobilized Clq-component of complement. Both drugs are being synthesized separately using the emulsion polymerization method in the gaseous nitrogen flow on the basis of polyacrylamide carrier with magnetic properties which is granulated at the 2:1 carrier: iron ratio. EFFECT: method provides for significant decrease of release of duplex DNA antibodies that are released into the blood flow in process of destruction of DNA-containing circulating immune complexes, while maintaining the effectiveness of destruction of said complexes. 1 dwg, 2 ex, 2 tbl |
|
Cyclophilin a - agent enhancing thrombocyte adhesion properties / 2435607 What is offered is an agent enhancing thrombocyte adhesion properties, representing cyclophilin A. It is shown that cyclophilin A not changing thrombocyte count increases collagen-induced thrombocyte aggregation without thrombin, and does not have an effect on ADP-induced and ristocetin-induced thrombocyte aggregation. |
 Pharmaceutical composition for treating cardiomyopathy / 2482865Invention refers to pharmaceutical industry, particularly to a pharmaceutical composition for treating cardiomyopathy. The method for preparing the pharmaceutical composition for treating cardiomyopathy of Astragalus, wormseed, water plantain, ginseng or sylvan codonopsis, silk vine bark or acanthopanax, cinnamon, mandarin bark, aconite, salvia miltiorrhiza bunge, Youzhu, saflona. The pharmaceutical composition for treating cardiomyopathy (versions). The use of the pharmaceutical composition for preparing the drug preparation (versions). |
FIELD: medicine.
SUBSTANCE: invention refers to medicine and is intended to prevent the age-related changes of hepatic tissue in rats experimentally. What is used is the biologically active additive "Rekicen RD" added to the diet of inbred laboratory rats at the age of two years old. A dose is 2 grams a day for 14 days.
EFFECT: method enables improving the hepatic tissue state ensured by increasing the regeneration activity of hepatocytes.
3 ex
The invention relates to the experimental medicine and can be used to activate the regeneration potential of the liver tissue of old laboratory animals, namely rats, aged two years. Rats at the age of two years is considered old (Saifutdinov A.I. Structural changes in hepatocytes of the white rats of different ages when you stay in conditions of high mountains (experimental study), author's abstract of dissertation for the degree of candidate of medical Sciences, Novosibirsk, 1994, 22 C.).
There are some age-related changes of the liver tissue. So, with age increases the number of hepatocytes with signs of damage and reduced regenerative capacity of the liver tissue (Saifutdinov A.I. Structural changes in hepatocytes of the white rats of different ages when you stay in conditions of high mountains (experimental study), author's abstract of dissertation for the degree of candidate of medical Sciences, Novosibirsk, 1994, 22 C.; Krokhin NB Age peculiarities of regenerative processes in the liver of patients with chronic active hepatitis, Avtoreferat Diss. on . very helpful and pleasant. step. kand. honey. of Sciences, Yekaterinburg, 2004, 127 S.). In the available literature is not found ways to prevent age-related changes of the liver tissue of old laboratory animals.
The technical result: the improvement of liver tissue by increasing the regenerative activity of hepatocytes.
This is achieved by adding a standard diet of laboratory animals of the product containing the fermented dietary fiber and short-chain fatty acids, dietary SUPPLEMENTS, «-RD ® » (production of JSC «Berry», Kirov), which is introduced in the diet for 2 grams per day for 14 days.
Way is as follows:
Old laboratory animals, namely rats aged two years contained on a standard diet vivarium, add to food product containing fermented dietary fiber and short-chain fatty acids, dietary SUPPLEMENTS, «-RD ® » (production company «Berry», Kirov), in the amount of 2 grams per day for 14 days.
For prophylaxis of age-related changes of the liver tissue of old laboratory animals, this product has not been previously used.
In the preparation of the liver, painted -eosin, using a light microscope using immersion (increase in 1000) in ten fields of view has been evaluated by the following indicators: the percentage of two - and hepatocytes, which is an indicator reflecting the regeneration of liver tissue, and the percentage of cells with signs of and , which is indicator, reflecting the damage to liver tissue ( IM Role of chorionic gonadotropin in the structural-functional provision of ontogenesis mammals in norm and pathology. 2003, http://www.medicum.nnov.ru/nmj/2003/1/14 .php; Saratikov A.S., A.V. Frolov, V.N. Chuchalin B.C. Correction toxicity of cyclophosphamide with liver protecting drugs polyphenol nature. Bulletin of Siberian medicine. - 2004, №1, P.52-56; E.V., I.A. Morphological changes in the liver and bodies of immunogenesis in cardiovascular diseases. Kursk scientific and practical Bulletin of the "People & health". - 2006, №4 - P.25-28).
BAD «-RD ® » (dietary fiber wheat bran, fermented wine yeast) (production company «Berry», Kirov) - biologically active additive to food, used to eliminate the deficit of food fibres and their metabolites (short-chain fatty acids in human nutrition. BAD «-RD ® » is used for prophylaxis and dietary treatment options of pathology, arising as a result of lack of fibre in the human diet (V.F. Kuznetsov, Kulemin L.M., V.M. Bondarenko Fermented dietary fiber and short-chain fatty acids in functional food in human pathology. Medical almanac. - 2008, №2 - p.88-89).
Examples of specific use:
Example 1.
Male white rats from the age of two, contained on a standard diet vivarium, mass 228 grams. When histological study of the drug liver percentage number of two - and three-nucleus nuclear hepatocytes amounted to 1.6%, the percentage of hepatocytes with signs and amounted to 35.5%.
Example 2.
Male white rats from the age of two, contained on a standard diet vivarium, received in addition BAD «-RD®» in the amount of 2 grams per day, a mass of 239 grams. In the study of liver histological slide the percentage of two - and three-nucleus hepatocytes was 10%, the percentage of hepatocytes with signs and amounted to 15%.
Example 3.
Male white rats from the age of two, contained on a standard diet vivarium, received in addition BAD «-RD®» in the amount of 2 grams per day, mass 316 grams. In the study of liver histological slide the percentage of two - and three-nucleus nuclear hepatocytes was 9,06%, the percentage of hepatocytes with signs and made 17.3%.
The entire study was conducted on 15 male white rats, aged two years. The animals were divided into two groups: a control group of animals that are on the standard diet of the control group (n=8), the experimental group - animals that are on the standard the diet of the control group (n=7), received in addition to a standard diet laboratory animals - BAD -RD®» (production of JSC «Berry», Kirov), on 2 grams per day for 14 days. Statistical processing of the obtained results was performed using the criteria of a non-parametric statistics. Calculate the median (Me), scale (25%-75%), to assess the reliability of differences between two unrelated groups have used double-sided (exact) Mann-Whitney criterion.
The percentage of two - and hepatocytes in the control group was 2,52% (1,27-3,63%), and in the experimental group 10,96% (9,34-13,25%) (p U =0,00058). The percentage of hepatocytes with signs and was in the control group 30,45% (24,46-35,55%), and in the experimental group 17.3% (to 14.32-19,97%) (p U =0,00233).
Positive effects of the appointment BAD «-RD®» old laboratory rats is the faithful increasing the quantity of fissile hepatocytes and reducing the number of cells with signs of damage that the totality of the evidence about the activation of regenerative processes of the liver and reducing the severity of age-related changes.
The method of prophylaxis of age-related changes of the liver tissue in the experiment, which consists in the fact that the old laboratory rats, located on the customary diet of the vivarium, within 14 days appoint BAD «-RD®» in the amount of 2 grams per day, mixing it with food.